Article
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
British journal of haematology - 1 Aug 2020
Wang Jing, Lu RunQing, Wu Ying, Jia JinSong, Gong Lizhong, Liu XiaoHong, Lu ShengYe, Wang Yu, Yan ChenHua, Liu KaiYan, Zhang XiaoHui, Xu LanPing, Jiang Qian, Zhao XiaoSu, Shi HongXia, Lai YueYun, Huang XiaoJun, Ruan GuoRui, Jiang Hao
Abstract excerpt
Acute myeloid leukaemia (AML) patients with biallelic mutations of CEBPA (bi CEBPA) have a 30-50% relapse rate. This study established the value of mutations based on next-generation sequencing (NGS) and multiparameter flow cytometric measurable residual disease (MFC-MRD) detection and compared the outcomes. From 2014 to 2018, 124 newly diagnosed bi CEBPA AML patients were treated. The median age was 37·5 (16-69)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.